Literature DB >> 16798122

A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.

Ming Zhao1, Michelle A Rudek, Ping He, Frank-Thorsten Hafner, Martin Radtke, John J Wright, B Douglas Smith, Wells A Messersmith, Manuel Hidalgo, Sharyn D Baker.   

Abstract

A rapid, sensitive and specific method was developed and validated using LC/MS/MS for determination of sorafenib in human plasma. Sample preparation involved a single protein precipitation step by the addition of 0.1 mL of plasma with 0.5 mL acetonitrile. Analysis of the compounds of interest including the internal standard ([(2)H(3)(15)N] sorafenib) was achieved on a Waters X-Terra C(18) (150 mm x 2.1mm i.d., 3.5 microm) analytical column using a mobile phase consisting of acetonitrile/10 mM ammonium acetate (65:35, v/v) containing 0.1% formic acid and isocratic flow at 0.2 mL/min for 6 min. The analytes were monitored by tandem mass spectrometry with electrospray positive ionization. Linear calibration curves were generated over the range of 7.3-7260 ng/mL for the human plasma samples with values for the coefficient of determination of >0.96. The values for both within day and between day precision and accuracy were well within the generally accepted criteria for analytical methods (<15%).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16798122     DOI: 10.1016/j.jchromb.2006.06.005

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  17 in total

1.  Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.

Authors:  Jeong Heo; Caroline J Breitbach; Anne Moon; Chang Won Kim; Rick Patt; Mi Kyung Kim; Yu Kyung Lee; Sung Yong Oh; Hyun Young Woo; Kelley Parato; Julia Rintoul; Theresa Falls; Theresa Hickman; Byung-Geon Rhee; John C Bell; David H Kirn; Tae-Ho Hwang
Journal:  Mol Ther       Date:  2011-03-22       Impact factor: 11.454

2.  Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry.

Authors:  Lie Li; Ming Zhao; Fariba Navid; Keith Pratz; B Doug Smith; Michelle A Rudek; Sharyn D Baker
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-09-09       Impact factor: 3.205

3.  Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.

Authors:  Lokesh Jain; Erin R Gardner; Jürgen Venitz; William Dahut; William D Figg
Journal:  J Pharm Biomed Anal       Date:  2008-01-22       Impact factor: 3.935

4.  Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.

Authors:  Ulka N Vaishampayan; Angelika M Burger; Edward A Sausville; Lance K Heilbrun; Jing Li; M Naomi Horiba; Merrill J Egorin; Percy Ivy; Simon Pacey; Patricia M Lorusso
Journal:  Clin Cancer Res       Date:  2010-06-04       Impact factor: 12.531

5.  Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.

Authors:  Shuiying Hu; Hongmei Niu; Hiroto Inaba; Shelley Orwick; Charles Rose; John C Panetta; Shengping Yang; Stanley Pounds; Yiping Fan; Christopher Calabrese; Jerold E Rehg; Dario Campana; Jeffrey E Rubnitz; Sharyn D Baker
Journal:  J Natl Cancer Inst       Date:  2011-04-12       Impact factor: 13.506

6.  Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.

Authors:  Tara C Gangadhar; Ezra E W Cohen; Kehua Wu; Linda Janisch; David Geary; Masha Kocherginsky; Larry K House; Jackie Ramirez; Samir D Undevia; Michael L Maitland; Gini F Fleming; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2011-03-29       Impact factor: 12.531

7.  Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.

Authors:  Nilofer Azad; Arvind Dasari; John Arcaroli; Gretchen E Taylor; Daniel A Laheru; Michael A Carducci; Martine McManus; Kevin Quackenbush; John J Wright; Manuel Hidalgo; Luis A Diaz; Ross C Donehower; Ming Zhao; Michelle A Rudek; Wells A Messersmith
Journal:  Invest New Drugs       Date:  2012-05-22       Impact factor: 3.850

8.  Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.

Authors:  Paola Di Gion; Friederike Kanefendt; Andreas Lindauer; Matthias Scheffler; Oxana Doroshyenko; Uwe Fuhr; Jürgen Wolf; Ulrich Jaehde
Journal:  Clin Pharmacokinet       Date:  2011-09       Impact factor: 6.447

Review 9.  Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Authors:  Keith Pratz; Mark Levis
Journal:  Leuk Lymphoma       Date:  2008-05

10.  Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.

Authors:  Shuiying Hu; Zhaoyuan Chen; Ryan Franke; Shelley Orwick; Ming Zhao; Michelle A Rudek; Alex Sparreboom; Sharyn D Baker
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.